Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Warning Letter Urges St. Gobain To Get Hip To QSR Regs

This article was originally published in The Gray Sheet

Executive Summary

Saint Gobain Advanced Ceramics Desmarquest did not adaquately verify and validate changes it made to its manufacturing process in 1998, FDA asserts in a recent warning letter outlining quality system reg (QSR) deficiencies related to certain artificial hip components

You may also be interested in...



Zimmer Will Seek Compensation From St. Gobain For Revision Surgery

Zimmer will pay non-reimbursed direct medical costs associated with revision surgery for patients who were implanted with certain recalled Saint Gobain Advanced Ceramic Desmarquest zirconia ceramic femoral heads distributed by the Warsaw, Indiana-based firm

French Health Authority Sparks Worldwide Recall of Zirconia Femoral Heads

The United Kingdom and Australia have issued device alert notices regarding the recall of Saint Gobain Advanced Ceramics Desmarquest zirconia ceramic femoral heads, following an Aug. 10 decision by the French government to suspend production and recall nine batches of the prosthetic hip components.

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

UsernamePublicRestriction

Register

OM003971

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel